Allianz Asset Management’s Beam Therapeutics BEAM Stock Holding History

Allianz Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$210K	Buy	+8,800	New	+$244K	﹤0.01%	1938
2022 Q1	–	Sell	-15,565	Closed	-$1.25M	–	2415
2021 Q4	$1.25M	Sell	15,565 -2,950	-16%	-$253K	﹤0.01%	1808
2021 Q3	$1.61M	Buy	18,515 +7,570	+69%	+$761K	﹤0.01%	1734
2021 Q2	$1.41M	Sell	10,945 -1,345	-11%	-$107K	﹤0.01%	1603
2021 Q1	$984K	Sell	12,290 -3,790	-24%	-$361K	﹤0.01%	1647
2020 Q4	$1.31M	Buy	+16,080	New	+$791K	﹤0.01%	1424

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Allianz Asset Management's BEAM Position: Q1 2026 in Review

Allianz Asset Management opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 8,800 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #1938 among its holdings. This is a return to the name: Allianz Asset Management previously reported a position in BEAM as recently as Q4 2021.

Allianz Asset Management first reported a position in BEAM in Q4 2020 and has held it in 6 quarters since. The position peaked at $1.61M in Q3 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

Allianz Asset Management held 8,800 shares of Beam Therapeutics worth $210K as of Q1 2026.
Beam Therapeutics was a new Allianz Asset Management position in Q1 2026.
Beam Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1938 holding.
Allianz Asset Management first reported a position in Beam Therapeutics in Q4 2020 and has held it in 6 quarters since.
Allianz Asset Management's Beam Therapeutics position peaked at $1.61M in Q3 2021.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.